Determination of Carboplatin's Optimal Plasmatic Exposure

I

Institut Claudius Regaud

Status

Completed

Conditions

Neoplasms

Treatments

Drug: Carboplatin

Study type

Interventional

Funder types

Other

Identifiers

NCT00145028
04 GENE 05

Details and patient eligibility

About

To determine Carboplatin's optimal exposures(optimal AUCs)and parameters they depend on.

Enrollment

400 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Carcinoma histologically proved and which must be treated by Carboplatin, excepted weekly administered Carboplatin treatments
  • Age > 18 years
  • Neutrophils > 1500/mm3, blood-platelets > 100000/mm3
  • Patient with intravenous administration route for chemotherapy independent of the one used for blood samples ( for Investigators centers achieving pharmacokinetic examination)
  • Well-informed written consent, signed by the patient

Exclusion criteria

  • Carboplatin treatment's contra-indication
  • Patient with clinically detectable cerebral metastasis
  • Pregnant or nursing women
  • Patient under guardianship or trusteeship
  • Patient whose venous status don't permit a peripheral intravenous administration route's placing (for Investigators centers achieving pharmacokinetic examination)

Trial contacts and locations

15

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems